The next dialogue and evaluation of the monetary situation and outcomes of operations of Nuo Therapeutics, Inc. ("Nuo Therapeutics," the "Firm," "we," "us," or "our") must be learn along side the monetary statements and associated notes showing elsewhere on this Quarterly Report and in our beforehand filed Annual Studies on Kind 10-Okay.
Sure statements, apart from purely historic data on this Quarterly Report (together with this part) represent "forward-looking statements".
Ahead-looking statements are inherently topic to dangers and uncertainties and precise outcomes and outcomes might differ materially from the outcomes and outcomes mentioned in or anticipated by the forward-looking statements.
Ahead-looking statements embrace, with out limitation, any assertion that will predict, forecast, point out, or suggest future outcomes, efficiency, or achievements, and will comprise the phrases "anticipate," "consider," "estimate," "anticipate," "intend," "will," "shall be," "will proceed," "will probably end result," "might," "might" and phrases of comparable import.
These statements replicate the Firm's present view of future occasions and are topic to sure dangers and uncertainties as famous on this Quarterly Report and in different stories filed by us with the Securities and Alternate Fee, together with Types 8-Okay, 10-Q, and 10-Okay.
These dangers and uncertainties embrace, amongst others, the next: Ought to a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes might differ materially from these anticipated in these forward-looking statements.
Along with the dangers recognized underneath the heading "Danger Elements" in our Annual Report and the opposite filings referenced above, different sections of this report might embrace extra elements which might adversely have an effect on our enterprise and monetary efficiency.
Furthermore, we function in a really aggressive and quickly altering setting.
New threat elements emerge now and again, and it's not potential for administration to foretell all such threat elements, nor can it assess the affect of all such threat elements on our enterprise, or the extent to which any issue, or mixture of things, might trigger precise outcomes to vary materially from these contained in any forward-looking statements.
Given these dangers and uncertainties, traders mustn't place undue reliance on forward-looking statements as a prediction of precise outcomes.
The Firm undertakes no obligation and doesn't intend to replace, revise or in any other case publicly launch any revisions to its forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the incidence of any unanticipated occasions.
We're a regenerative therapies firm centered on growing and advertising and marketing merchandise for continual wound care primarily throughout the U.S.
We commercialize revolutionary cell-based applied sciences that harness the regenerative capability of the human physique to set off pure therapeutic.
The usage of autologous (i.e., from self, the affected person's personal) organic therapies for tissue restore and regeneration is a part of a medical technique designed to enhance long-term restoration in inherently advanced continual situations with important unmet medical wants. -------------------------------------------------------------------------------- Desk of Contents Our present business providing consists of a degree of care know-how for the secure and efficient separation of autologous blood to supply a platelet-based remedy for the continual wound care market.
This providing is named "Aurix" or the "Aurix System".
The FDA cleared the Aurix System for advertising and marketing in 2007 as a tool underneath Part 510(ok) of the Federal Meals, Drug, and Beauty Act ("FDCA").
Aurix is one in all two platelet derived merchandise cleared by the FDA for continual wound care use and is indicated for many exuding wounds.
The superior wound care market, inside which Aurix competes, consists of superior wound care dressings, wound care gadgets, and wound care biologics, and is estimated to be an approximate .4 billion international market, with the variety of sufferers affected by all types of continual wounds projected to extend worldwide at a price of roughly eight % per 12 months by 2025.
The Aurix System produces a platelet wealthy plasma ("PRP") gel on the level of care utilizing the affected person's personal platelets and plasma sourced from a small draw of peripheral blood.
Aurix includes a pure, endogenous complement of protein and non-protein sign molecules that contribute to efficient therapeutic.
Throughout remedy, the affected person's platelets are activated and launch a whole lot of progress issue proteins and different signaling molecules that kind a biologically lively hematogel.
Aurix delivers concentrations of the pure complement of cytokines, progress elements and chemokines which are identified to control angiogenesis (i.e., the event of recent blood vessels), cell progress, and the formation of recent tissue.
As soon as utilized to the ready wound mattress, the biologically lively Aurix hematogel can restore the steadiness within the wound setting to rework a non-healing wound to a wound that heals naturally.
In 2012, a Medicare Nationwide Protection Dedication ("NCD") from CMS reversed a twenty-year outdated non-coverage determination for autologous blood derived merchandise utilized in wound care.
This NCD allowed for Medicare protection underneath the Protection with Proof Improvement ("CED") program.
CED packages have been employed for a specific quantity number of different therapies, together with transcatheter aortic valve restore and cochlear implantation.
Below the CED program, CMS supplies reimbursement for gadgets or providers on the situation that they be furnished in authorised medical protocols or within the assortment of extra medical knowledge.
Below the CED program, a facility treating a affected person with Aurix was reimbursed by Medicare when well being outcomes knowledge have been collected to tell future protection choices.
The intent of the CED program is to judge the outcomes of Aurix remedy for the broader Medicare inhabitants when it's utilized in a "actual world" continuum of care.
In Could 2019, we transmitted a letter memorandum to CMS' Protection and Evaluation Group ("CAG") in assist of our full formal request for reconsideration of the then current nationwide protection willpower primarily based on medical knowledge collected and revealed underneath the CED program.
The whole formal public request for reconsideration was made on Could 8, 2019 in accordance with the relevant necessities.
On April 13, 2021, CMS issued a last protection determination memo indicating that Medicare would nationally cowl autologous PRP for the remedy of continual non-healing diabetic wounds for a length of 20 weeks underneath Part 1862(a)(1)(A) of the Social Safety Act.
This protection applies when utilizing gadgets whose FDA-cleared indications embrace the administration of exuding cutaneous wounds, reminiscent of diabetic ulcers.
Protection of autologous PRP past 20 weeks for diabetic foot ulcers and for the remedy of all different continual, non-diabetic, non-healing wounds shall be decided by native Medicare Administrative Contractors.
Though FDA cleared the Aurix System for advertising and marketing in 2007 underneath Part 510(ok) of the FDCA, CMS solely established economically viable reimbursement for the product starting in 2016.
For 2022, the Medicare nationwide common reimbursement price for the Aurix System is ,749 per remedy, which we consider supplies acceptable cost to amenities for product utilization.
Over the interval from the cessation of regular operational actions in Could 2019 by the ultimate NCD in April 2021 and resulting in the late 2021 determination to reinitiate enterprise actions, the Firm was centered on partaking with CMS as acceptable, monitoring the developments regarding our reconsideration request, advancing our positions throughout varied public remark durations and sustaining total but restricted company viability within the occasion {that a} sufficiently favorable protection and reimbursement setting developed for Aurix.
As well as, the Firm took actions throughout this era to deal with its capital construction by eliminating each its debt and exchanging the Collection A Most popular Inventory issued on the time of the Could 2016 recapitalization for frequent inventory.
The Science Underlying Aurix/Platelet Wealthy Plasma The science underlying wound therapeutic is well-established.
A direct early occasion essential for wound therapeutic is the inflow of platelets to the wound website.
Platelets bind to components inside broken tissue reminiscent of collagen fragments and endogenous thrombin molecules and are activated to launch a range of progress elements and different biomolecules from their alpha and dense granules (Reed 2000, Nieswandt, 2003).
These biomolecules present alerts important for organic responses regulating hemostasis and efficient tissue regeneration. -------------------------------------------------------------------------------- Dysregulation of quite a few mobile and organic responses contribute to the continual wound phenotype.
Continual wounds have diminished ranges of progress elements and concomitant decreases in mobile proliferation (Mast 1996).
There may be elevated mobile senescence (Telgenhoff 2005), and there typically is an absence of perfusion that may inhibit the supply of vitamins and cells required for regeneration (Guo 2010).
Because the physique makes an attempt to stave off an infection, elevated concentrations of free radicals accumulate within the continual wound and additional harm surrounding tissue (Moseley 2004, James 2003).
Aurix has been cleared by FDA as secure and efficient with a sign for continual wounds reminiscent of leg ulcers, strain ulcers, and diabetic ulcers and different exuding wounds reminiscent of mechanically or surgically debrided wounds.
The Aurix therapeutic is shaped by mixing a pattern of a affected person's platelets and plasma with pharmaceutical grade thrombin and ascorbic acid.
The thrombin prompts platelets whereas ascorbic acid drives the synthesis of excessive tensile energy collagen, clears damaging free radicals and controls gel consistency.
The topical dermal utility of Aurix gel bypasses the shortage of native perfusion to offer speedy alerts for brand new tissue formation and finally therapeutic.
The Efficacy of Aurix Pertains to Organic Exercise Launched by Platelets Greater than 300 proteins are launched by human platelets in response to thrombin activation (Coppinger 2004).
Essential examples embrace vascular endothelial cell progress issue ("VEGF"), platelet derived progress issue ("PDGF"), epidermal progress issue ("EGF"), fibroblast progress issue ("FGF") and reworking progress factor-beta ("TGF-B") (Eppley 2004, Everts 2006).
These proteins are essential for organized wound therapeutic, regulating responses reminiscent of vascularization, cell proliferation, cell differentiation, and deposition of recent extracellular matrix (Goldman 2004).
Platelets additionally launch chemokines reminiscent of Interleukin-8 ("IL-8"), stromal cell derived factor-1 ("SDF-1"), and platelet factor-4 ("PF-4") (Chatterjee 2011, Gear 2003) that management the mobilization and migration of stem cells and fibroblasts (Werner 2003 and Gillitzer 2001), which contribute to tissue regeneration.
Populations of bioburden in continual wounds range over time and wounds invariably retain or change into re-infected with some degree of micro organism that's detrimental to therapeutic (Howell-Jones 2005).
Along with regenerative capability, platelets launch anti-microbial peptides efficient in opposition to a broad vary of pathogens together with Methicillin Resistant Staphylococcus Aureus ("MRSA") (Moojen 2007, Jia 2010, Tang 2002, Bielecki 2007).
A number of efficacy and effectiveness research have been revealed in peer reviewed journals documenting the affect of utilizing Aurix to deal with continual wounds.
Key knowledge embrace: -------------------------------------------------------------------------------- Comparability of Three Months Ended September 30, 2021 and 2020 The quantities offered on this comparability part are rounded to the closest thousand.
There have been no revenues or gross revenue within the three months ended September 30, 2021 and 2020 because the Firm ceased ongoing operational actions efficient Could 1, 2019 and now not handled topics underneath the earlier CED program whereas promoting its remaining Aurix stock over the steadiness of 2019. [Re-initiation of commercial activity for the Aurix product began in May 2022 as saleable product inventory became available at the Texas warehouse/distribution facility.] Complete working bills for the three months ending September 30, 2021 and 2020 have been nominal and fewer that ,000 within the quarter.
The one bills incurred have been directed in the direction of sustaining minimal firm viability.
There was no different earnings (expense) for the three months ended September 30, 2021 whereas the Firm acknowledged roughly ,000 of curiosity expense on the 2019 Senior Secured Notes for the three months ended September 30, 2020.
Comparability of 9 Months Ended September 30, 2021 and 2020 The quantities offered on this comparability part are rounded to the closest thousand.
There have been no revenues or gross revenue within the 9 months ended September 30, 2021 and 2020 because the Firm ceased ongoing operational actions efficient Could 1, 2019 and now not handled topics underneath the earlier CED program whereas promoting its remaining Aurix stock over the steadiness of 2019. [Re-initiation of commercial activity for the Aurix product began in May 2022 as saleable product inventory became available at the Texas warehouse/distribution facility.] Complete working bills for the 9 months ended September 30, 2021 totaled a nominal approximate ,000 and decreased roughly ,000 in comparison with the 9 months ended September 30, 2020.
There was no different earnings (expense) for the 9 months ended September 30, 2021 compared to internet different earnings of roughly 7,000 within the 9 months ended September 30, 2020.
Curiosity expense of roughly ,000 on the 2019 Senior Secured Notes was offset by the acquire of roughly 6,000 on debt extinguishment on the 2018 Convertible Notes.
Liquidity and Capital Sources As of September 30, 2021, we had money and money equivalents of roughly The next dialogue and evaluation of the monetary situation and outcomes of operations of Nuo Therapeutics, Inc. ("Nuo Therapeutics," the "Firm," "we," "us," or "our") must be learn along side the monetary statements and associated notes showing elsewhere on this Quarterly Report and in our beforehand filed Annual Studies on Kind 10-Okay.
Sure statements, apart from purely historic data on this Quarterly Report (together with this part) represent "forward-looking statements".
Ahead-looking statements are inherently topic to dangers and uncertainties and precise outcomes and outcomes might differ materially from the outcomes and outcomes mentioned in or anticipated by the forward-looking statements.
Ahead-looking statements embrace, with out limitation, any assertion that will predict, forecast, point out, or suggest future outcomes, efficiency, or achievements, and will comprise the phrases "anticipate," "consider," "estimate," "anticipate," "intend," "will," "shall be," "will proceed," "will probably end result," "might," "might" and phrases of comparable import.
These statements replicate the Firm's present view of future occasions and are topic to sure dangers and uncertainties as famous on this Quarterly Report and in different stories filed by us with the Securities and Alternate Fee, together with Types 8-Okay, 10-Q, and 10-Okay.
These dangers and uncertainties embrace, amongst others, the next: Ought to a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes might differ materially from these anticipated in these forward-looking statements.
Along with the dangers recognized underneath the heading "Danger Elements" in our Annual Report and the opposite filings referenced above, different sections of this report might embrace extra elements which might adversely have an effect on our enterprise and monetary efficiency.
Furthermore, we function in a really aggressive and quickly altering setting.
New threat elements emerge now and again, and it's not potential for administration to foretell all such threat elements, nor can it assess the affect of all such threat elements on our enterprise, or the extent to which any issue, or mixture of things, might trigger precise outcomes to vary materially from these contained in any forward-looking statements.
Given these dangers and uncertainties, traders mustn't place undue reliance on forward-looking statements as a prediction of precise outcomes.
The Firm undertakes no obligation and doesn't intend to replace, revise or in any other case publicly launch any revisions to its forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the incidence of any unanticipated occasions.
We're a regenerative therapies firm centered on growing and advertising and marketing merchandise for continual wound care primarily throughout the U.S.
We commercialize revolutionary cell-based applied sciences that harness the regenerative capability of the human physique to set off pure therapeutic.
The usage of autologous (i.e., from self, the affected person's personal) organic therapies for tissue restore and regeneration is a part of a medical technique designed to enhance long-term restoration in inherently advanced continual situations with important unmet medical wants. -------------------------------------------------------------------------------- Desk of Contents Our present business providing consists of a degree of care know-how for the secure and efficient separation of autologous blood to supply a platelet-based remedy for the continual wound care market.
This providing is named "Aurix" or the "Aurix System".
The FDA cleared the Aurix System for advertising and marketing in 2007 as a tool underneath Part 510(ok) of the Federal Meals, Drug, and Beauty Act ("FDCA").
Aurix is one in all two platelet derived merchandise cleared by the FDA for continual wound care use and is indicated for many exuding wounds.
The superior wound care market, inside which Aurix competes, consists of superior wound care dressings, wound care gadgets, and wound care biologics, and is estimated to be an approximate $13.4 billion international market, with the variety of sufferers affected by all types of continual wounds projected to extend worldwide at a price of roughly eight % per 12 months by 2025.
The Aurix System produces a platelet wealthy plasma ("PRP") gel on the level of care utilizing the affected person's personal platelets and plasma sourced from a small draw of peripheral blood.
Aurix includes a pure, endogenous complement of protein and non-protein sign molecules that contribute to efficient therapeutic.
Throughout remedy, the affected person's platelets are activated and launch a whole lot of progress issue proteins and different signaling molecules that kind a biologically lively hematogel.
Aurix delivers concentrations of the pure complement of cytokines, progress elements and chemokines which are identified to control angiogenesis (i.e., the event of recent blood vessels), cell progress, and the formation of recent tissue.
As soon as utilized to the ready wound mattress, the biologically lively Aurix hematogel can restore the steadiness within the wound setting to rework a non-healing wound to a wound that heals naturally.
In 2012, a Medicare Nationwide Protection Dedication ("NCD") from CMS reversed a twenty-year outdated non-coverage determination for autologous blood derived merchandise utilized in wound care.
This NCD allowed for Medicare protection underneath the Protection with Proof Improvement ("CED") program.
CED packages have been employed for a specific quantity number of different therapies, together with transcatheter aortic valve restore and cochlear implantation.
Below the CED program, CMS supplies reimbursement for gadgets or providers on the situation that they be furnished in authorised medical protocols or within the assortment of extra medical knowledge.
Below the CED program, a facility treating a affected person with Aurix was reimbursed by Medicare when well being outcomes knowledge have been collected to tell future protection choices.
The intent of the CED program is to judge the outcomes of Aurix remedy for the broader Medicare inhabitants when it's utilized in a "actual world" continuum of care.
In Could 2019, we transmitted a letter memorandum to CMS' Protection and Evaluation Group ("CAG") in assist of our full formal request for reconsideration of the then current nationwide protection willpower primarily based on medical knowledge collected and revealed underneath the CED program.
The whole formal public request for reconsideration was made on Could 8, 2019 in accordance with the relevant necessities.
On April 13, 2021, CMS issued a last protection determination memo indicating that Medicare would nationally cowl autologous PRP for the remedy of continual non-healing diabetic wounds for a length of 20 weeks underneath Part 1862(a)(1)(A) of the Social Safety Act.
This protection applies when utilizing gadgets whose FDA-cleared indications embrace the administration of exuding cutaneous wounds, reminiscent of diabetic ulcers.
Protection of autologous PRP past 20 weeks for diabetic foot ulcers and for the remedy of all different continual, non-diabetic, non-healing wounds shall be decided by native Medicare Administrative Contractors.
Though FDA cleared the Aurix System for advertising and marketing in 2007 underneath Part 510(ok) of the FDCA, CMS solely established economically viable reimbursement for the product starting in 2016.
For 2022, the Medicare nationwide common reimbursement price for the Aurix System is $1,749 per remedy, which we consider supplies acceptable cost to amenities for product utilization.
Over the interval from the cessation of regular operational actions in Could 2019 by the ultimate NCD in April 2021 and resulting in the late 2021 determination to reinitiate enterprise actions, the Firm was centered on partaking with CMS as acceptable, monitoring the developments regarding our reconsideration request, advancing our positions throughout varied public remark durations and sustaining total but restricted company viability within the occasion {that a} sufficiently favorable protection and reimbursement setting developed for Aurix.
As well as, the Firm took actions throughout this era to deal with its capital construction by eliminating each its debt and exchanging the Collection A Most popular Inventory issued on the time of the Could 2016 recapitalization for frequent inventory.
The Science Underlying Aurix/Platelet Wealthy Plasma The science underlying wound therapeutic is well-established.
A direct early occasion essential for wound therapeutic is the inflow of platelets to the wound website.
Platelets bind to components inside broken tissue reminiscent of collagen fragments and endogenous thrombin molecules and are activated to launch a range of progress elements and different biomolecules from their alpha and dense granules (Reed 2000, Nieswandt, 2003).
These biomolecules present alerts important for organic responses regulating hemostasis and efficient tissue regeneration. -------------------------------------------------------------------------------- Dysregulation of quite a few mobile and organic responses contribute to the continual wound phenotype.
Continual wounds have diminished ranges of progress elements and concomitant decreases in mobile proliferation (Mast 1996).
There may be elevated mobile senescence (Telgenhoff 2005), and there typically is an absence of perfusion that may inhibit the supply of vitamins and cells required for regeneration (Guo 2010).
Because the physique makes an attempt to stave off an infection, elevated concentrations of free radicals accumulate within the continual wound and additional harm surrounding tissue (Moseley 2004, James 2003).
Aurix has been cleared by FDA as secure and efficient with a sign for continual wounds reminiscent of leg ulcers, strain ulcers, and diabetic ulcers and different exuding wounds reminiscent of mechanically or surgically debrided wounds.
The Aurix therapeutic is shaped by mixing a pattern of a affected person's platelets and plasma with pharmaceutical grade thrombin and ascorbic acid.
The thrombin prompts platelets whereas ascorbic acid drives the synthesis of excessive tensile energy collagen, clears damaging free radicals and controls gel consistency.
The topical dermal utility of Aurix gel bypasses the shortage of native perfusion to offer speedy alerts for brand new tissue formation and finally therapeutic.
The Efficacy of Aurix Pertains to Organic Exercise Launched by Platelets Greater than 300 proteins are launched by human platelets in response to thrombin activation (Coppinger 2004).
Essential examples embrace vascular endothelial cell progress issue ("VEGF"), platelet derived progress issue ("PDGF"), epidermal progress issue ("EGF"), fibroblast progress issue ("FGF") and reworking progress factor-beta ("TGF-B") (Eppley 2004, Everts 2006).
These proteins are essential for organized wound therapeutic, regulating responses reminiscent of vascularization, cell proliferation, cell differentiation, and deposition of recent extracellular matrix (Goldman 2004).
Platelets additionally launch chemokines reminiscent of Interleukin-8 ("IL-8"), stromal cell derived factor-1 ("SDF-1"), and platelet factor-4 ("PF-4") (Chatterjee 2011, Gear 2003) that management the mobilization and migration of stem cells and fibroblasts (Werner 2003 and Gillitzer 2001), which contribute to tissue regeneration.
Populations of bioburden in continual wounds range over time and wounds invariably retain or change into re-infected with some degree of micro organism that's detrimental to therapeutic (Howell-Jones 2005).
Along with regenerative capability, platelets launch anti-microbial peptides efficient in opposition to a broad vary of pathogens together with Methicillin Resistant Staphylococcus Aureus ("MRSA") (Moojen 2007, Jia 2010, Tang 2002, Bielecki 2007).
A number of efficacy and effectiveness research have been revealed in peer reviewed journals documenting the affect of utilizing Aurix to deal with continual wounds.
Key knowledge embrace: -------------------------------------------------------------------------------- Comparability of Three Months Ended September 30, 2021 and 2020 The quantities offered on this comparability part are rounded to the closest thousand.
There have been no revenues or gross revenue within the three months ended September 30, 2021 and 2020 because the Firm ceased ongoing operational actions efficient Could 1, 2019 and now not handled topics underneath the earlier CED program whereas promoting its remaining Aurix stock over the steadiness of 2019. [Re-initiation of commercial activity for the Aurix product began in May 2022 as saleable product inventory became available at the Texas warehouse/distribution facility.] Complete working bills for the three months ending September 30, 2021 and 2020 have been nominal and fewer that $10,000 within the quarter.
The one bills incurred have been directed in the direction of sustaining minimal firm viability.
There was no different earnings (expense) for the three months ended September 30, 2021 whereas the Firm acknowledged roughly $9,000 of curiosity expense on the 2019 Senior Secured Notes for the three months ended September 30, 2020.
Comparability of 9 Months Ended September 30, 2021 and 2020 The quantities offered on this comparability part are rounded to the closest thousand.
There have been no revenues or gross revenue within the 9 months ended September 30, 2021 and 2020 because the Firm ceased ongoing operational actions efficient Could 1, 2019 and now not handled topics underneath the earlier CED program whereas promoting its remaining Aurix stock over the steadiness of 2019. [Re-initiation of commercial activity for the Aurix product began in May 2022 as saleable product inventory became available at the Texas warehouse/distribution facility.] Complete working bills for the 9 months ended September 30, 2021 totaled a nominal approximate $19,000 and decreased roughly $35,000 in comparison with the 9 months ended September 30, 2020.
There was no different earnings (expense) for the 9 months ended September 30, 2021 compared to internet different earnings of roughly $197,000 within the 9 months ended September 30, 2020.
Curiosity expense of roughly $48,000 on the 2019 Senior Secured Notes was offset by the acquire of roughly $246,000 on debt extinguishment on the 2018 Convertible Notes.
Liquidity and Capital Sources As of September 30, 2021, we had money and money equivalents of roughly $0.1 million, whole present belongings of roughly $0.1 million and whole present liabilities of roughly $0.7 million.
As of September 30, 2021, our collected deficit was roughly $24.5 million and our stockholders' deficit was roughly $0.5 million.
As of September 30, 2022, we had money and money equivalents of roughly $[2.9] million, whole present belongings of roughly $[3.5] million and whole present liabilities of roughly $[0.4] million.
As an operational enterprise, we now have a historical past of losses and will not be at present worthwhile.
For the years ended December 31, 2021, 2020, and 2019, we incurred internet losses of roughly $0.1 million, $0.1 million, and $1.2 million, respectively.
As of September 30, 2022, our collected deficit was roughly $[25.7] million and our stockholders' fairness was roughly $[3.2] million. -------------------------------------------------------------------------------- Desk of Contents Primarily based on our present working forecast, we consider that our current money and money equivalents, after making an allowance for the capital transactions in 2022, shall be ample to fund our operations by a minimum of the following 12 months.
Financing and Associated Developments In the course of the Years 2019 by 2022 Spring 2019 Cessation of Regular Working Actions In April 2019, the Firm made the choice to stop regular operational actions and we furloughed the Firm's remaining staff efficient Could 1, 2019.
This determination was necessitated by the depletion of the Firm's assets throughout the conduct of the CED research being undertaken to pursue Medicare reimbursement protection for the Aurix System.
Within the spring of 2019, we had collected medical outcomes and analyzed the info from the topics concerned within the CED research and have been engaged in discussions with CMS regarding the adequacy of the outcomes and a NCD reconsideration request.
On December 10, 2019, the Firm entered into fifth and last amendments to the 2018 Convertible Notes pursuant to which the Firm's obligations underneath such notes have been to be extinguished of their entirety upon receipt by every Convertible Notice Investor of (i) a money cost of $110,000 and (ii) 175,000 unrestricted shares of the Firm's frequent inventory no later than February 10, 2020.
The Firm made the required money funds totaling $220,000 on December 10, 2019 and issued the frequent shares as of February 5, 2020 in last settlement of the 2018 Convertible Notes.
On November 15, 2019 and December 6, 2019, the Firm entered into word buy agreements with sure particular person accredited traders (the "Senior Notice Traders") for the issuance and sale to the Traders of 12% senior secured promissory notes (the "Senor Notes"), within the mixture principal quantity of $305,000 with an total $500,000 cap underneath the word buy agreements.
Pursuant to the acquisition agreements, the Firm additionally issued to the Senior Notice Traders warrants exercisable to buy an mixture 457,500 shares of the Firm's frequent inventory, topic to adjustment as referenced beneath.
At the side of the word issuance, the Firm granted a first-priority safety curiosity in all of the belongings of the Firm however essentially consisting of the Aurix System asset together with all regulatory information and approvals and related mental property.
The acquisition agreements contained sure representations, warranties and covenants by, amongst and for the advantage of the respective events.
The acquisition agreements additionally offered for customary indemnification of the Senior Notice Traders by the Firm.
The notes had a maturity date of June 30, 2020 and accrued curiosity at a price of 12% per 12 months.
The Firm might prepay the Senior Notes, in entire or partially, at any time.
The warrants have been exercisable at any time, at an train worth per share equal to $0.40, topic to sure changes and worth safety provisions (together with full ratchet anti-dilution safety) contained within the warrants.
The warrants had five-year phrases.
The usage of proceeds from the Notes past the preliminary $50,000 and as much as an estimated mixture quantity of $270,000 was particularly devoted to cost to the 2018 Convertible Notice Traders, in a last quantity to be agreed between the Firm and the Convertible Notice Traders such that the 2018 Convertible Notes have been thought-about retired and now not in impact.
Collection A Most popular Inventory Alternate Settlement On October 5, 2020, the Firm entered right into a Recapitalization Settlement (the "Recap Settlement) with Deerfield Personal Design Fund II, L.P. ("DPDF") and Deerfield PDI Financing II, L.P. ("DPF" and, along with DPDF, the "Deerfield Traders") and the Noteholders, whereby the shares of Collection A most well-liked inventory held by the Deerfield Traders have been exchanged for two,700,000 shares of frequent inventory of the Firm.
The Senior Notice Traders agreed to the conversion of the $305,000 principal steadiness of the Notes plus accrued curiosity by September 30, 2020 of roughly $30,400 into an mixture 838,487 shares of frequent inventory of the Firm at a conversion worth of $0.40 per share, plus the acquisition, for money, of 487,500 shares of frequent inventory at $0.40 per share, or $195,000 in whole.
As of October 5, 2020, all shares of Collection A most well-liked inventory and Senior Notes have been cancelled in full.
Pursuant to the Recap Settlement, the Firm additionally issued to the Senior Notice Traders warrants to buy an mixture of three,977,961 shares of the Firm's frequent inventory, topic to adjustment as referenced beneath.
The warrants have been exercisable at any time, at an train worth per share equal to $0.40, topic to sure changes and worth safety provisions contained within the warrants.
The warrants had five-year phrases.
The warrants to buy 457,500 shares of frequent inventory issued to the Noteholders upon the unique 2019 issuance of the Notes have been canceled. -------------------------------------------------------------------------------- Desk of Contents Warrant Modification Settlement and Early Warrant Train Efficient as of December 1, 2021, the Firm entered right into a Warrant Modification Settlement (the "WMA") with the holders of an mixture 6,865,461 Warrants whereby the Warrants have been modified to regulate the warrant train worth from $0.40 per share to $0.20 per share offered the Investor exercised the warrant previous to January 31, 2022.
All Warrants not exercised previous to January 31, 2022 have been to be forfeited and deemed expired or in any other case cancelled.
As of December 30, 2021, all Warrants had been exercised for whole consideration of $1,373,092 and the ensuing issuance of 6,865,461 shares of frequent inventory.
In the course of the 9 months ended September 30, 2022, the Firm raised proceeds of $4,457,757 from the sale of frequent inventory to sure accredited traders in three separate fairness non-public placements which closed in April, Could, and September 2022.
Internet money offered by (utilized in) working, investing, and financing actions for the durations offered have been as follows: Money flows utilized in working actions $ (13,002 ) $ (20,253 ) Money flows utilized in investing actions $ Money utilized in working actions for the 9 months ended September 30, 2021 of roughly $13,000 primarily displays our internet lack of roughly $19,000 as adjusted by a nominal internet change in working belongings and liabilities.
Money utilized in working actions for the 9 months ended September 30, 2020 was roughly $20,000 and primarily displays our internet earnings of roughly $143,000 adjusted by the $246,000 acquire on debt extinguishment and a internet change in working belongings and liabilities.
Investing Actions Investing Actions There have been no investing actions for the 9 months ended September 30, 2021 and 2020.
There have been no financing actions for the 9 months ended September 30, 2021 and 2020.
The Firm believes that the charges of inflation in recent times haven't had a big affect on its operations.
Off-Steadiness Sheet Preparations The Firm doesn't have any off-balance sheet preparations.
Crucial Accounting Insurance policies Our consolidated monetary statements included in Half I, Merchandise 1 of this Quarterly Report are ready in conformity with U.S.
GAAP, which require us to make estimates and assumptions concerning future occasions that have an effect on the quantities reported in our monetary statements and accompanying notes.
We base these estimates on our expertise and assumptions concerning future occasions we consider to be cheap underneath the circumstances.
Precise outcomes might differ from these estimates and such variations could also be materials to the consolidated monetary statements.
We now have described our most crucial accounting insurance policies within the "Administration's Dialogue and Evaluation of Monetary Situation and Outcomes of Operations" part of our most just lately filed Annual Studies on Kind 10-Okay.. -------------------------------------------------------------------------------- Desk of Contents © Edgar On-line, supply Glimpses source